Last Updated: August 3, 2026

DELTALIN Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Deltalin, and when can generic versions of Deltalin launch?

Deltalin is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in DELTALIN is ergocalciferol. There are six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ergocalciferol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Deltalin

A generic version of DELTALIN was approved as ergocalciferol by CHARTWELL RX on May 20^th, 2009.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for DELTALIN?
What are the global sales for DELTALIN?
What is Average Wholesale Price for DELTALIN?

Summary for DELTALIN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DELTALIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	DELTALIN	ergocalciferol	CAPSULE;ORAL	080884-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.